Overview
Inluriyo is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that has progressed following at least one line of endocrine therapy. Treatment eligibility requires the presence of an ESR1 gene mutation (change), which should be confirmed through testing. Inluriyo is also known by its drug name, imlunestrant.

Inluriyo is an estrogen receptor antagonist. It works by blocking the activity of estrogen receptors, which can slow or stop the growth of breast cancer cells that rely on estrogen to grow.

How do I take it?
Prescribing information states that Inluriyo is taken orally as a tablet once daily on an empty stomach. The recommended dosing schedule is one dose per day. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Inluriyo include decreased hemoglobin, musculoskeletal pain, low calcium levels, decreased neutrophils (a type of white blood cell), increased levels of AST and ALT (liver enzymes), fatigue, diarrhea, increased triglycerides and cholesterol, nausea, low platelet levels, constipation, and abdominal pain.

Rare but serious side effects may include embryo-fetal toxicity, which means the drug can cause harm to an unborn baby. People taking Inluriyo should use effective birth control and avoid becoming pregnant during treatment.

For more information about this treatment, visit:
Inluriyo (Imlunestrant) Tablets, for Oral Use — Eli Lilly and Company